What is F2G?
F2G is dedicated to pioneering innovative science to create effective antifungal treatments, emphasizing a patient-first approach. The company's core mission involves developing novel therapies targeting rare and life-threatening fungal infections, particularly those caused by resistant pathogens. With a tenacious team, F2G aims to expand therapeutic options for vulnerable patient populations, contributing to the advancement of life-saving treatments in a critical area of unmet medical need.
How much funding has F2G raised?
F2G has raised a total of $347.9M across 8 funding rounds:
Series A
$6.1M
Private Equity
$9.2M
Other Financing Round
$11.8M
Private Equity
$30M
Series C
$60M
Series D
$60.8M
Unspecified
$70M
Other Financing Round
$100M
Series A (2002): $6.1M, investors not publicly disclosed
Private Equity (2008): $9.2M, investors not publicly disclosed
Other Financing Round (2008): $11.8M supported by Merifin Capital, BankInvest Biomedical Venture, K Nominees, and Astellas Venture Management
Private Equity (2012): $30M featuring Sunstone Capital, Astellas Venture Management, Advent Life Sciences, Novartis BioVenture Fund, and Merifin Capital
Series C (2016): $60M backed by Novo A/S, Aisling Capital, Sunstone Capital, Advent Life Sciences, Brace Pharma Capital, Merifin Capital, Sectoral Asset Management, and Novartis Venture Fund
Series D (2020): $60.8M with participation from Brace Pharma Capital, Novo Holdings, Morningside Ventures, Cowen Healthcare Investments, and Advent Life Sciences
Unspecified (2022): $70M led by Sofinnova Partners, Morningside Venture Capital, Cowen Healthcare Investments, Novo Holdings, Advent Life Sciences, and Forbion
Other Financing Round (2024): $100M supported by Sofinnova Partners, Novo Holdings, Advent Life Sciences, The AMR Action Fund, and ICG
Key Investors in F2G
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. They are known for their hands-on approach in building companies across the entire value chain of life sciences investments.
Novo Holdings
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focusing on investments within the life sciences sector.
Advent Life Sciences
Advent Life Sciences is a leading trans-Atlantic venture capital firm focused on building innovative life sciences businesses, specializing in early and mid-stage investments in companies developing novel medicines and medical products.
What's next for F2G?
The substantial enterprise-level funding secured by F2G positions the company for accelerated growth and the advancement of its therapeutic pipeline. This strategic investment is expected to fuel further research and development, potentially enabling F2G to move its novel antifungal therapies through clinical trials and towards market approval. The company's focus on rare and life-threatening infections suggests a trajectory aimed at addressing significant public health challenges and providing critical treatment options for underserved patient groups.
See full F2G company page
